ECM
VNDA icon

EMC Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

EMC Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,185
Closed -$176K – 304
2022
Q2 		$176K Sell
16,185
-6,900
-30% -$71.5K 0.15% 143
2022
Q1 		$229K Buy
+23,085
New +$303K 0.16% 93

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

EMC Capital Management's VNDA Position: Q3 2022 in Review

EMC Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2022, closing a stake of 16,185 shares — an estimated $176K sold.

EMC Capital Management first reported a position in VNDA in Q1 2022 and held it in 2 quarters. The position peaked at $229K in Q1 2022. 178 funds tracked by Wall St. Rank hold VNDA as of Q3 2022.

  • EMC Capital Management reported no remaining Vanda Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • EMC Capital Management sold 16,185 Vanda Pharmaceuticals shares in Q3 2022, an estimated $176K.
  • EMC Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • EMC Capital Management's Vanda Pharmaceuticals position peaked at $229K in Q1 2022.
  • 178 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2022.

Based on EMC Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.